Identifying Mucormycosis Severity in Indian COVID-19 Patients: A Nano-Based Diagnosis and the Necessity for Critical Therapeutic Intervention

The COVID-19 infection caused by the new SARS-CoV-2 virus has been linked to a broad spectrum of symptoms, from a mild cough to life-threatening pneumonia. As we learn more about this unusual COVID-19 epidemic, new issues are emerging and being reported daily. Mucormycosis, also known as zygomycosis...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Syed Mohammed Basheeruddin Asdaq, Arya Rajan, Aswin Damodaran, Shivali R. Kamath, Krishnanjana S. Nair, Subin Mary Zachariah, Ram Kumar Sahu, Santosh Fattepur, Nagaraja Sreeharsha, Anroop Nair, Shery Jacob, Hussain A. Albahrani, Eman H. Alkhaldi, Yahya Mohzari, Ahmed A. Alrashed, Mohd. Imran
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	COVID-19 mucormycosis nanotechnology antifungal diabetes diagnosis Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/fdd41567703c452e88a45bbee7c93556
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Identifying Mucormycosis Severity in Indian COVID-19 Patients: A Nano-Based Diagnosis and the Necessity for Critical Therapeutic Intervention

Documents similaires